Pohl Christin, Zalar Matja, Bialy Inas El, Indrakumar Sowmya, Peters Günther H J, Friess Wolfgang, Golovanov Alexander P, Streicher Werner W, Noergaard Allan, Harris Pernille
Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark.
Department of Chemistry, Technical University of Denmark, Kemitorvet 207, 2800 Kongens, Lyngby, Denmark.
Mol Pharm. 2020 Sep 8;17(9):3298-3313. doi: 10.1021/acs.molpharmaceut.0c00406. Epub 2020 Aug 7.
Therapeutic peptides and proteins show enormous potential in the pharmaceutical market, but high costs in discovery and development are limiting factors so far. Single or multiple point mutations are commonly introduced in protein drugs to increase their binding affinity or selectivity. They can also induce adverse properties, which might be overlooked in a functional screen, such as a decreased colloidal or thermal stability, leading to problems in later stages of the development. In this study, we address the effect of point mutations on the stability of the 4.4 kDa antimicrobial peptide plectasin, as a case study. We combined a systematic high-throughput biophysical screen of the peptide thermal and colloidal stability using dynamic light scattering and differential scanning calorimetry with structure-based methods including small-angle X-ray scattering, analytical ultracentrifugation, and nuclear magnetic resonance spectroscopy. Additionally, we applied molecular dynamics simulations to link obtained protein stability parameters to the protein's molecular structure. Despite their predicted structural similarities, all four plectasin variants showed substantially different behavior in solution. We observed an increasing propensity of plectasin to aggregate at a higher pH, and the introduced mutations influenced the type of aggregation. Our strategy for systematically assessing the stability and aggregation of protein drugs is generally applicable and is of particular relevance, given the increasing number of protein drugs in development.
治疗性肽和蛋白质在制药市场显示出巨大潜力,但迄今为止,发现和开发成本高昂是限制因素。蛋白质药物中通常引入单点或多点突变以提高其结合亲和力或选择性。它们也可能引发不良特性,而这些特性在功能筛选中可能被忽视,比如胶体稳定性或热稳定性降低,从而在开发后期导致问题。在本研究中,作为一个案例研究,我们探讨了点突变对4.4 kDa抗菌肽plecatin稳定性的影响。我们将使用动态光散射和差示扫描量热法对肽的热稳定性和胶体稳定性进行的系统高通量生物物理筛选与基于结构的方法(包括小角X射线散射、分析超速离心和核磁共振光谱)相结合。此外,我们应用分子动力学模拟将获得的蛋白质稳定性参数与蛋白质的分子结构联系起来。尽管预测它们的结构相似,但所有四种plecatin变体在溶液中的行为却大不相同。我们观察到plecatin在较高pH值下聚集的倾向增加,并且引入的突变影响了聚集类型。鉴于正在开发的蛋白质药物数量不断增加,我们系统评估蛋白质药物稳定性和聚集的策略普遍适用且尤为重要。